Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Marylène Leboeuf"'
Autor:
Jean Davoust, Pascal Chappert, Philippe Rameau, Mélanie Lalfer, Marylène Leboeuf, Sabine Desbois, Olivier Danos, Roland S. Liblau, David-Alexandre Gross
Publikováno v:
European Journal of Immunology. 40:339-350
Foxp3(+) Treg are crucial for the maintenance of self-tolerance and have been shown to control CD8(+) T-cell effector functions. In addition, Treg are thought to control the priming of CD8(+) T cells, which recognize the same antigens as Treg. Taking
Autor:
Sylvain Paisant, Olivier Danos, Marylène Leboeuf, Philippe Rameau, Isabelle Barde, Christophe Delenda, Maria Antonietta Zanta-Boussif
Publikováno v:
Molecular Therapy. 13:382-390
This work addresses the problem of efficient control of gene expression in the context of viral vectors, which still represents a difficult challenge. A number of lentiviral vectors incorporating the different elements of regulatable transcriptional
Autor:
Georges Uzan, Anne Dubart-Kupperschmitt, A. Schmitt, C. Lavenu-Bombled, Jean-Philippe Rosa, Véronique Briquet-Laugier, Marylène Leboeuf
Publikováno v:
Journal of Thrombosis and Haemostasis. 2:2231-2240
Summary. The storage mechanism of endogenous secretory proteins in megakaryocyte α-granules is poorly understood. We have elected to study the granule storage of platelet factor 4 (PF4), a well-known platelet α-granule protein. The reporter protein
Autor:
Jean-Luc Plantier, Nathalie Enjolras, Muriel Réa, Marie-Hélène Rodriguez, Georges Uzan, Marylène Leboeuf, Claude Negrier
Publikováno v:
British Journal of Haematology. 127:568-575
SummaryHaemophilia A is an attractive target for gene therapy. We designed ahaemophilia A gene therapy strategy involving the genetic modification ofhaematopoietic stem cells to achieve tissue-specific expression of a factor VIII(FVIII) transgene i
Autor:
Mihaela Crisan, Xu Hui Liu, Pierre Charbord, Marylène Leboeuf, Heidi Bompais, Georges Uzan, Xavier Canron, Aurora Anjo, Andreas Bikfalvi, Carine Tolla-Le Port, Jalila Chagraoui
Publikováno v:
Blood. 103:2577-2584
Endothelial progenitor cells (EPCs) were shown to be present in systemic circulation and cord blood. We investigated whether EPCs display specific properties compared with mature endothelial cells. Human cord blood CD34+ cells were isolated and adher
Autor:
C Doucet, Marylène Leboeuf, Jean Davoust, Florent Ginhoux, François A. Lemonnier, Olivier Danos, Hüseyin Firat
Publikováno v:
Molecular Therapy. 8:274-283
Dystrophin-based gene therapy treatments aimed at correcting the Duchenne muscular dystrophy phenotype require stable expression of normal dystrophin (DYST) protein in myocytes without immune responses, which would compromise long-term expression. To
Autor:
Jean-Luc Plantier, Georges Uzan, M. Rea, Jean-Claude Bordet, Claude Negrier, Nathalie Enjolras, Marylène Leboeuf, M. H. Rodriguez
Publikováno v:
Thrombosis and Haemostasis. 87:366-373
SummaryWe have developed a gene therapy project for haemophilia B which aims to express factor IX (FIX) in haematopoietic lineage. Haematopoietic stem cells and subsequent megakaryocyte-derived cells represent the target cells of this approach. Our s
Autor:
Adeline Lepage, Marylène Leboeuf, Jean-Pierre Cazenave, Corinne de la Salle, François Lanza, Georges Uzan
Publikováno v:
Blood. 96:4169-4177
Megakaryocytopoiesis is a complex multistep process involving cell division, endoreplication, and maturation and resulting in the release of platelets into the blood circulation. Megakaryocytes (MK) progressively express lineage-restricted proteins,
Publikováno v:
Blood. 102:4326-4328
Like cellular transplantation, gene therapy is often limited by immune rejection of the newly expressed antigen. In a model of gene transfer in muscle, delivery of the influenza hemagglutinin (HA) membrane protein by adeno-associated virus (AAV) is i
Autor:
Pascal Chappert, Marylène Leboeuf, Olivier Danos, Laetitia van Wittenberghe, David-Alexandre Gross, Virginie Monteilhet, Jean Davoust
Publikováno v:
Blood. 108(6)
A major impediment to gene replacement therapy is immune elimination of genetically modified cells. In principle, this can be dealt with by inducing a strong, specific, and enduring tolerance through engraftment of transgene-modified autologous bone